What is your approach to the management of anti-pruritic therapies in patients with cholestatic liver disease?  

If the patient has PBC, the newer FDA PPAR drugs (elafibranor and seladelpar) for PBC have an anti-pruritic effect, though they are mainly approved to lower ALP and are thought to be disease-modifying. For PFIC and Allagille syndrome, IBAT inhibitors (odevixibat and maralixibat) are helpful and are...